webleads-tracker

Transparency in Europe: 2016 and Beyond

In June 2013, the EFPIA (European Federation of Pharmaceutical Industries and Associations) Statutory General Assembly adopted the “EFPIA code”, a code set by industry self-regulation, requiring its 33 national member associations to publicly report the transfers of value (ToV) made by pharmaceutical companies to physicians (HCPs), and healthcare organizations (HCOs).Pharma Compliance Digital CRM Marketing Transparence DMOS EFPIA Transparency in Europe: 2016 and Beyond
The underlying objective was to increase transparency around interactions between industry and HCPs and HCOs, to proactively address potential concerns in society around these interactions.
Three years later, on June 30, 2016, the deadline set for the implementation passed. For the first time, member companies published their ToVs, disclosing their interactions with HCPs and HCOs for 2015. Whilst transparency initiatives in themselves are not new (the US has already had experience reporting ToVs under the US Sunshine Act, and in other countries transparency initiatives where already in place as well, such as in France (Loi Bertrand), the Netherlands (transparentieregister), Portugal (Infarmed) and the UK (ABPI)), this was the first time that transparency reporting happened in so many countries at the same time.
Now, several months after the deadline has passed, is an opportune time to look back and reflect: what were experiences leading up to the deadline, what happened so far, and what can we expect going forward?

To read the article by Geert van Gansewinkel

Check Also

Conflicts of interests, transparency, transparence des liens d'intérêts, sunshine act, loi bertrand

EMA policy on the handling of competing interests of scientific committees’ members and experts

EU legislation clearly states that the members of the scientific committees and experts shall not …